Related references
Note: Only part of the references are listed.Cancer Risk after Cyclophosphamide Treatment in Idiopathic Membranous Nephropathy
Jan A. J. G. van den Brand et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Long-Term Outcomes in Idiopathic Membranous Nephropathy Using a Restrictive Treatment Strategy
Jan A. J. G. van den Brand et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (HP ActharA® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy
Michelle A. Hladunewich et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis
Laurence Beck et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Immunosuppression for Membranous Nephropathy: A Systematic Review and Meta-Analysis of 36 Clinical Trials
Yizhi Chen et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial
Andrew Howman et al.
LANCET (2013)
Treatment of Resistant Glomerular Diseases with Adrenocorticotropic Hormone Gel: A Prospective Trial
Andrew S. Bomback et al.
AMERICAN JOURNAL OF NEPHROLOGY (2012)
Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
E. Robak et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Rituximab in Idiopathic Membranous Nephropathy
Piero Ruggenenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
OPINION The renaissance of corticotropin therapy in proteinuric nephropathies
Rujun Gong
NATURE REVIEWS NEPHROLOGY (2012)
Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy
Emily P. McQuarrie et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study
Paolo Cravedi et al.
AMERICAN JOURNAL OF NEPHROLOGY (2011)
Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study
Radomir Naumovic et al.
BIOMEDICINE & PHARMACOTHERAPY (2011)
Risk HLA-DQA1 and PLA(sub 2)R1 Alleles in Idiopathic Membranous Nephropathy.
Horia C. Stanescu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Tacrolimus Combined With Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled Trial
Min Chen et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2010)
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fernando C. Fervenza et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Melanocortin 1 Receptor Agonists Reduce Proteinuria
Annika Lindskog et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Successful Treatment of Membranous Glomerulonephritis with Rituximab in Calcineurin Inhibitor-Dependent Patients
Alfons Segarra et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
M-Type Phospholipase A(sub 2) Receptor as Target Antigen in Idiopathic Membranous Nephropathy.
Laurence H. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mycophenolate mofetil monotherapy in membranous nephropathy: A 1-year randomized controlled trial
Bertrand Dussol et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Rituximab treatment of idiopathic membranous nephropathy
F. C. Fervenza et al.
KIDNEY INTERNATIONAL (2008)
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A
Christian Faul et al.
NATURE MEDICINE (2008)
Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study
Lakshmanan Senthil Nayagam et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Long-term study of mycophenolate mofetil as both induction and maintenance treatment for diffuse proliferative lupus nephritis
Tak Mao Chan et al.
NEPHROLOGY (2007)
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy
Paolo Cravedi et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide
Amanda J. Branten et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy
Vivekanand Jha et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Tacrolimus monotherapy in membranous nephropathy:: A randomized controlled trial
M. Praga et al.
KIDNEY INTERNATIONAL (2007)
Rituximab for idiopathic membranous nephropathy: Who can benefit?
Piero Ruggenenti et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy
C Ponticelli et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
Rituximab in idiopathic membranous nephropathy: A one year prospective study
P Ruggenenti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Rituximab for idiopathic membranous nephropathy
G Remuzzi et al.
LANCET (2002)
Intravenous immunoglobulin g in the treatment of patients with chronic glomerulonephritis: Clinical experience lasting 15 years
D Monova et al.
NEPHRON (2002)
Mycophenolate mofetil treatment for primary glomerular diseases
MJ Choi et al.
KIDNEY INTERNATIONAL (2002)
Use of mycophenolate mofetil in resistant membranous nephropathy
G Miller et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2000)
Share Paper
